Workflow
AURORA(600666)
icon
Search documents
今日共73只个股发生大宗交易,总成交32.19亿元
Di Yi Cai Jing· 2025-09-26 09:45
Group 1 - A total of 73 stocks experienced block trades in the A-share market on September 26, with a total transaction value of 3.219 billion yuan [1] - The top three stocks by transaction value were Pudong Development Bank (782 million yuan), Guangqi Technology (273 million yuan), and Zhongwei Company (244 million yuan) [1] - Among the stocks, 10 were traded at par, 7 at a premium, and 56 at a discount; Dongfang Caifu, Aerospace Hongtu, and Taiping Bird had the highest premium rates of 15.08%, 9.14%, and 7.37% respectively [1] Group 2 - The top stocks by institutional buy amounts included Ningde Times (224 million yuan), Zhongwei Company (217 million yuan), and Haiguang Information (127 million yuan) [1] - The top stocks by institutional sell amounts were Ningde Times (187 million yuan), Jinkang Electric (101 million yuan), and Jinkai New Energy (37.29 million yuan) [2] - The MACD golden cross signal has formed, indicating a positive trend for certain stocks [2]
奥瑞德今日大宗交易折价成交500万股,成交额1580万元
Xin Lang Cai Jing· 2025-09-25 09:39
| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-25 | 奥瑞德 | 600666 | 3.16 1580 | 500 | 机构专用 | 去筒素泵劈船甚雾 | | 197 | 9月25日,奥瑞德大宗交易成交500万股,成交额1580万元,占当日总成交额的5.89%,成交价3.16元, 较市场收盘价3.44元折价8.14%。 ...
奥瑞德(600666) - 奥瑞德关于持股5%以上股东股份被第二次司法拍卖的进展公告
2025-09-24 11:33
2025 年 9 月 24 日,公司查询了"阿里拍卖·司法"网络平台,根据平台发布的竞 价结果确认书,确认拍卖结果如下: 褚淑霞持有的 65,152,000 股公司股票,由买受人张逸君竞拍所得,拍卖成交价格 60,509,520 元。 1 重要内容提示: 一、本次拍卖的基本情况 公司于 2025 年 9 月 11 日披露了《关于持股 5%以上股东股份将被第二次司法拍卖 的提示性公告》(公告编号:临 2025-038),黑龙江省哈尔滨市中级人民法院立案执行 江海证券有限公司与褚淑霞国内非涉外仲裁裁决一案,拟于 2025 年 9 月 23 日 10 时至 2025 年 9 月 24 日 10 时在"阿里拍卖·司法"(sf.taobao.com)第二次公开拍卖褚淑 霞持有的 65,152,000 股公司股票(股份性质为限售股,占其与其一致行动人所持公司 股份的 27.46%,占公司股份总数的 2.36%)。 二、本次拍卖的进展情况 证券代码:600666 证券简称:奥瑞德 公告编号:临2025-040 奥瑞德光电股份有限公司 关于持股 5%以上股东股份被 第二次司法拍卖的进展公告 本公司董事会及全体董事保证本公告内 ...
奥瑞德今日大宗交易折价成交500万股,成交额1615万元
Xin Lang Cai Jing· 2025-09-24 09:32
| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-24 | 奥瑞德 | 600666 | 3.23 | تينج | 500 | 机构专用 | 中信证券股价值娱 公司北京房柳证券 | 9月24日,奥瑞德大宗交易成交500万股,成交额1615万元,占当日总成交额的5.53%,成交价3.23元,较市场收盘价3.51元折价7.98%。 ...
短线防风险 171只个股短期均线现死叉
Market Overview - The Shanghai Composite Index closed at 3821.83 points, with a decline of 0.18% [1] - The total trading volume of A-shares reached 25,184.71 billion yuan [1] Technical Analysis - A total of 171 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.60 yuan, 10-day MA at 23.25 yuan, a difference of -2.80% [1] - Xiangyu Medical: 5-day MA at 54.48 yuan, 10-day MA at 55.33 yuan, a difference of -1.54% [1] - Northern Long Dragon: 5-day MA at 122.21 yuan, 10-day MA at 123.92 yuan, a difference of -1.38% [1] Stock Performance - Key stocks with notable declines include: - Innovation Medical: down 2.97% with a turnover rate of 16.99% [1] - Xiangyu Medical: down 5.95% with a turnover rate of 2.14% [1] - Northern Long Dragon: down 2.23% with a turnover rate of 20.67% [1] - Other stocks with significant declines include: - Aorui: down 5.25% [1] - Changbai Mountain: down 7.15% [1] - Hengbao Shares: down 6.73% [1]
短线防风险 228只个股短期均线现死叉
Market Overview - The Shanghai Composite Index closed at 3781.61 points, with a decline of 1.23% [1] - The total trading volume of A-shares reached 1713.539 billion yuan [1] Technical Analysis - A total of 228 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.55 yuan, 10-day MA at 23.23 yuan, a difference of -2.92% [1] - North Long Dragon: 5-day MA at 121.67 yuan, 10-day MA at 123.65 yuan, a difference of -1.60% [1] - Xiangyu Medical: 5-day MA at 54.49 yuan, 10-day MA at 55.34 yuan, a difference of -1.53% [1] Individual Stock Performance - Significant declines in stock prices include: - Innovation Medical: down 4.27% with a turnover rate of 14.36% [1] - North Long Dragon: down 4.52% with a turnover rate of 13.85% [1] - Xiangyu Medical: down 5.86% with a turnover rate of 1.42% [1] - Other notable declines: - Shandong Mining Machine: down 4.43% [1] - Huakang Clean: down 6.50% [1] - Beautiful Ecology: down 5.15% [1] Additional Stock Data - The following stocks also showed significant declines: - Yuyin Co.: down 5.46% [2] - Kexin Information: down 5.22% [1] - Visual China: down 3.88% [1] - Stocks with notable trading activity include: - Hengbao: down 6.64% with a turnover rate of 10.88% [2] - Changbai Mountain: down 6.53% with a turnover rate of 4.05% [2]
奥瑞德今日大宗交易折价成交468.25万股,成交额1559.27万元
Xin Lang Cai Jing· 2025-09-22 09:38
Group 1 - On September 22, a block trade of 4.6825 million shares of Aorede was executed, with a transaction amount of 15.5927 million yuan, accounting for 5.87% of the total transaction amount for that day [1] - The transaction price was 3.33 yuan, which represents an 8.01% discount compared to the market closing price of 3.62 yuan [1]
奥瑞德:原实控人所持公司2.35亿股股份被轮候冻结
Core Viewpoint - The announcement reveals that major shareholders of Aorede (600666) have had their shares frozen by the Harbin Intermediate People's Court due to ongoing debt disputes and performance compensation obligations, impacting the company's stock and governance structure [1][2][3] Group 1: Shareholder Actions - Major shareholders Chu Shuxia and Zuo Hongbo have had a total of 235 million shares frozen, representing 8.52% of the company's total equity, with the freeze starting on September 12, 2025, for a period of 36 months [1] - The frozen shares include 151 million shares held by Chu Shuxia and 84.27 million shares held by Zuo Hongbo, accounting for 5.47% and 3.05% of the total equity, respectively [1] Group 2: Performance Compensation Obligations - The performance compensation obligation for Zuo Hongbo and Chu Shuxia amounts to 391 million shares, with the company applying for enforcement through the Harbin Intermediate People's Court [2] - Due to other debt disputes, the recovery of performance compensation shares and cash remains highly uncertain [2] Group 3: Historical Context and Financial Performance - Aorede's acquisition of 100% equity from Southwest Pharmaceutical in 2015 involved a share swap and a cash component of 3.338 billion yuan, leading to Zuo Hongbo and Chu Shuxia becoming controlling shareholders [2] - Aorede committed to a cumulative net profit of no less than 1.216 billion yuan from 2015 to 2017, but the actual net profit was only 648 million yuan, achieving a completion rate of 53% [3] - Due to underperformance, Zuo Hongbo and Chu Shuxia are liable for 99.52% of the compensation obligations, which may lead to forced judicial auction of their shares [3]
奥瑞德(600666) - 奥瑞德关于持股5%以上股东股份被轮候冻结的公告
2025-09-16 09:16
证券代码:600666 证券简称:奥瑞德 公告编号:临2025-039 1 / 3 | 波 | | % | % | | -9- | 自转为正 | 哈尔滨市 | 绩补偿事 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 12 | 式冻结之 | 中级人民 | 宜申请执 | | | | | | | | 日起计算 | 法院 | 行 | | | | | | | 2025 | 36 个月, | 黑龙江省 | 公司因业 | | 左洪 | 74,271,715 | 88.13 | 2.69 | 是 | -9- | 自转为正 | 哈尔滨市 | 绩补偿事 | | 波 | | % | % | | 12 | 式冻结之 | 中级人民 | 宜申请执 | | | | | | | | 日起计算 | 法院 | 行 | | 合计 | 235,423,715 | - | 8.52 | - | - | - | - | - | | | | | % | | | | | | 奥瑞德光电股份有限公司 关于持股 5%以上股东股份被轮候冻结的公告 本公司董事会及全体董事 ...
珠江股份拟择机出售所持部分股票资产 预计收益占上年净利润50%以上
Zhi Tong Cai Jing· 2025-09-10 12:41
Core Viewpoint - The company plans to sell a total of 8.686 million shares of Guizhou Yibai Pharmaceutical, 970,600 shares of Aorui De, 7,716 shares of China Ping An, and 4.7122 million shares of Hunan Erkang Pharmaceutical, aiming to optimize its asset structure and improve liquidity and efficiency [1] Group 1 - The estimated profit from the sale of these stocks, after deducting costs and taxes, is expected to exceed 50% of the company's audited net profit for the last year [1] - The sale is intended to enhance the company's asset liquidity and utilization [1] - The company is strategically timing the sale based on stock market conditions [1]